Anna Torgeson
Overview
Explore the profile of Anna Torgeson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
104
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ager B, Torgeson A, Francis S, Burt L, Gaffney D, Cannon D
Am J Clin Oncol
. 2019 Nov;
43(1):35-42.
PMID: 31764024
Objectives: We examined the impact of brachytherapy boost (BB) and external beam radiotherapy (EBRT) dose-escalation on overall survival (OS) for women with cervical cancer receiving postoperative chemotherapy and radiation (CRT)...
2.
Tao R, Ager B, Lloyd S, Torgeson A, Denney M, Gaffney D, et al.
J Gastrointest Oncol
. 2019 Jan;
9(6):1044-1053.
PMID: 30603123
Survival for upper gastrointestinal tumors remains poor, likely in part due to treatment resistance associated with intratumoral hypoxia. In this review, we highlight advances in nuclear medicine imaging that allow...
3.
Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd S
J Gastrointest Oncol
. 2019 Jan;
9(6):1014-1026.
PMID: 30603120
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, with its mortality rate approaching its incidence rate every year. Accordingly, much interest has been generated in harnessing the immune system in...
4.
Torgeson A, Tao R, Garrido-Laguna I, Willen B, Dursteler A, Lloyd S
J Gastrointest Oncol
. 2019 Jan;
9(6):996-1004.
PMID: 30603118
We sought to review published aggregate dataset studies on pancreatic cancer in the national and international settings, discuss the advantages and disadvantages these datasets possess, and possible future directions. A...
5.
Coffman A, Torgeson A, Lloyd S
Ann Surg Oncol
. 2018 Aug;
26(1):98-108.
PMID: 30145650
Background: Surgical resection is the most important therapeutic intervention for eligible patients with pancreatic cancer; however, a majority of patients never receive surgery for a variety of reasons, including patient...
6.
Torgeson A, Garrido-Laguna I, Tao R, Cannon G, Scaife C, Lloyd S
ESMO Open
. 2018 Feb;
3(1):e000282.
PMID: 29387477
Background: Surgical resection remains the best chance at long-term survival in pancreatic cancer, though margin-positive resections are associated with diminished survival. We examined the effect of margin-positive resection on survival,...
7.
Torgeson A, Lloyd S, Boothe D, Cannon G, Garrido-Laguna I, Whisenant J, et al.
Ann Surg Oncol
. 2017 Oct;
24(13):4001-4008.
PMID: 29043526
Background: Unresected extrahepatic cholangiocarcinoma (uEHCC) remains a deadly disease. Guidelines for uEHCC recommend either chemotherapy alone (CT) or chemoradiotherapy (CRT). This study used the National Cancer Database (NCDB) to compare...
8.
Torgeson A, Boothe D, Poppe M, Suneja G, Gaffney D
Gynecol Oncol
. 2017 Aug;
147(2):320-328.
PMID: 28802765
Purpose: Elderly women with endometrial cancer are at increased risk of local recurrence and cancer-specific death compared to younger women. We sought to investigate adjuvant radiotherapy (RT) practice patterns and...
9.
Torgeson A, Lloyd S, Boothe D, Tao R, Whisenant J, Garrido-Laguna I, et al.
Cancer
. 2017 Jun;
123(19):3816-3824.
PMID: 28621885
Background: The role of chemoradiotherapy (CRT) in locally advanced pancreatic cancer (LAPC) is uncertain after multiple randomized clinical trials have yielded mixed results. The authors used the National Cancer Data...